(CUS.L) CustomVis PLC Buy/Sell

RNS Number : 0187H CustomVis plc 11 February 2010

11 February 2010

CustomVis plc

("CustomVis" or "the Company")

Result of AGM

CustomVis (AIM: CUS), the leading developer, manufacturer and distributor of solid state laser systems for the refractive surgical industry is pleased to announce that at today's AGM all resolutions were duly passed.

RNS Number : 9890G CustomVis plc 11 February 2010

11 February 2010

CustomVis plc

("CustomVis" or "the Company")

AGM Statement

At the Annual General Meeting of CustomVis to be held at 10.00 a.m. this morning, Simon Carroll, Chairman of the Company, will make the following statement:

"The Group has made a positive start to 2010, with a further contract for a laser into South America, which is quickly becoming one of our strongest territories. We continue our endeavours in other countries, where advanced negotiations are underway with a number of surgeons, some of which we expect to conclude in the coming weeks.

We are very pleased to report that our market opportunities have expanded with the regulatory approval to perform our PresBvis* treatment for presbyopia, the condition that leads to the need for reading glasses. Indeed, our CEO, Paul van Saarloos, has recently become one of the first patients to undergo corrective surgery for presbyopia, using our newly pioneered PresBvis* technique. We can report that his vision has been fully restored in the treated eye and he no longer needs glasses for reading, something he has done for the past 3 years. A key benefit from the ability to perform the PresBvis* treatment is that surgeons have another reason to acquire the Pulzar Z1 laser as it provides them with another substantial market to address.

The directors expect the rest of the year to be an exciting one for the Group as we continue to make advances in our laser technology. We are also now seeing our first revenues from PresBvis* and later in the calendar year, we expect to make the first sales for RetinaVis*, our new portable digital ophthalmoscope which photographs the retina of the eye. Negotiations with distributors for large volumes are currently underway.

Our key sales focus in 2010 will be on the mature European market, following the recent appointment of our European sales representative. This market promises to deliver higher margins to the Group and, the current series of clinical trials which are underway at Moorfields Hospital should hopefully provide the evidence we need to set ourselves favourably against the strongest of our competitors. The Moorfields trial is aiming to treat more difficult cases of irregular shaped eyes that traditionally have very few or no other options for treatment. Therefore, it is likely that the trial will take some time to complete and it is unlikely the full results will be available until later this calendar year.

CustomVis plans to announce its interim results in late March, when we will update shareholders more thoroughly with our various developments."

RNS Number : 7611F CustomVis plc 19 January 2010

19 January 2010

CUSTOMVIS PLC

("CustomVis" or the "Company")

Directorate Change

CustomVis is pleased to announce the appointment of Mr Stuart Douglas Usher, aged 40, as a non-executive director of the Company with immediate effect. Mr Usher is a Certified Practicing Accountant (CPA) and a Chartered Company Secretary. He will join the Finance and Audit Committee of the Board and continue as Company Secretary. He has over 15 years experience in the management and corporate affairs of public listed companies including extensive engagement in technology-focused companies.

Mr Usher, who has held the position of part-time CFO since May 2009, will step down from this role on 31 January 2010. The Company has appointed Mr Imerio Bresciani as full-time financial controller, with effect from 1 February 2010. Mr Bresciani is a CPA and has considerable experience in management accounting, audit and IT management. Mr Bresciani has worked in companies with multinational endeavours including a global healthcare products company.

During the last five years, Mr Usher was previously a director of Advanced Ocular Systems Limited. Mr Usher has confirmed that he has no current directorships other than the Company. Mr Usher does not hold any shares in the issued share capital of the Company.

Mr Usher has confirmed that there are no further details to be disclosed in accordance with Schedule Two paragraph (g) of the AIM Rules.

CustomVis Chairman, Simon Carroll, commented, "We are delighted that Stuart has agreed to join the Board where his experience will immediately benefit the Finance and Audit Committee. At the same time it is with great pleasure that we welcome Imerio into his role as financial controller. Having the finance department run by a full-time, experienced accounting professional with knowledge of the healthcare sector was a number one priority for the Company, especially now we are experiencing greater levels of interest in the Pulzar Z1, many of which we hope to convert into sales."

ENQUIRIES:

CustomVis plc
Simon Carroll, Chairman +61 419 304 906
Paul van Saarloos, CEO +61 410 497 456

Merchant John East Securities Limited
David Worlidge 020 7628 2200

Leander PR
Christian Taylor-Wilkinson 07795 168 157

This information is provided by RNS The company news service from the London Stock Exchange

BOAQKLBFBFFXBBB

RNS Number : 7612F CustomVis plc 19 January 2010

19 January 2010

CustomVis plc

("CustomVis" or "the Company")

Notice of AGM

CustomVis announces that it has today posted to shareholders of the Company (the "Shareholders") a circular giving notice of an annual general meeting (the "AGM") to be held at 10.00 a.m. on 11 February 2010 (the "Notice").

The business of the AGM will be to receive the report and accounts and to conduct other ordinary and special business of the Company as set out in the Notice.

Special business

At the AGM a resolution will be proposed to renew the directors' authority to allot shares (or securities carrying rights to subscribe for or to convert into shares) outside employee share schemes, limited to a maximum of 180,000,000 ordinary shares in the capital of the Company. A further resolution will be proposed to seek approval to disapply statutory pre-emption rights which require that any shares to be allotted for cash (other than under employee share schemes) must first be offered to existing shareholders. This authority is in respect of the grant of options to Dr Paul van Saarloos in respect of up to 20,000,000 ordinary shares in the capital of the Company ("Ordinary Shares") and is otherwise limited to a maximum of 160,000,000 Ordinary Shares.

As noted in the annual report and accounts for the year to 30 June 2009, which was posted to Shareholders on 31 December 2009, the Directors continue to implement developments to fund ongoing operations and growth. One option being considered by the Directors is to raise additional working capital in the course of 2010 and the authority sought under this resolution will give the Directors flexibility to raise capital, should this be necessary in the best interests of the Company, without following the strict statutory pre-emption provisions and potentially delaying a fundraising.

The Board has restructured the employment conditions of the CEO, Dr Paul van Saarloos and the options proposed to be granted to Dr van Saarloos are outside the existing share option scheme approved by the Company's shareholders on 13 December 2004. They are in respect of 20,000,000 Ordinary Shares and will contribute to his employment conditions through a 24 per cent. reduction in his direct salary and a comprehensive incentive program over the next three years. The options are at exercise prices and vesting dates as described in the table below and are subject to certain performance criteria being achieved:

No of Options Exercise Price Vesting Date Expiry of Option
Tranche 1 5,000,000 £0.02 30 June 2010 30 June 2015
Tranche 2 5,000,000 £0.03 30 June 2011 31 Dec 2016
Tranche 3 2,000,000 £0.045 30 June 2011 30 June 2016
Tranche 4 4,000,000 £0.06 30 June 2012 30 June 2017
Tranche 5 4,000,000 £0.10 30 June 2012 30 June 2017
20,000,000

These authorities will expire at the next annual general meeting of the Company or, if earlier, 15 months from the date of passing of this resolution.

For further information, please contact:

CustomVis plc
Simon Carroll, Chairman +61 419 304 906
Paul van Saarloos, CEO +61 410 497 456

Merchant John East Securities Limited
David Worlidge / Simon Clements 020 7628 2200

Leander PR
Christian Taylor-Wilkinson 07795 168 157

This information is provided by RNS The company news service from the London Stock Exchange

NOAGLGDBSXBBGGC